8.0185
Precedente Chiudi:
$7.96
Aprire:
$7.98
Volume 24 ore:
86,535
Relative Volume:
0.05
Capitalizzazione di mercato:
$2.51B
Reddito:
$2.68B
Utile/perdita netta:
$-184.45M
Rapporto P/E:
-11.78
EPS:
-0.6805
Flusso di cassa netto:
$229.23M
1 W Prestazione:
-2.92%
1M Prestazione:
+1.31%
6M Prestazione:
-8.98%
1 anno Prestazione:
+7.92%
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Nome
Amneal Pharmaceuticals Inc
Settore
Telefono
908-947-3120
Indirizzo
400 Crossing Boulevard, 3rd Floor, Bridgewater
Confronta AMRX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
AMRX
Amneal Pharmaceuticals Inc
|
8.02 | 2.59B | 2.68B | -184.45M | 229.23M | -0.6805 |
![]()
ZTS
Zoetis Inc
|
152.09 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.72 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.745 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.59 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
302.44 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-06-06 | Iniziato | Goldman | Buy |
2025-02-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
2024-09-06 | Aggiornamento | JP Morgan | Underweight → Neutral |
2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
2021-03-08 | Aggiornamento | Goldman | Sell → Buy |
2020-12-14 | Aggiornamento | Barclays | Equal Weight → Overweight |
2020-12-14 | Aggiornamento | Guggenheim | Neutral → Buy |
2020-07-27 | Iniziato | Goldman | Sell |
2020-05-12 | Aggiornamento | Guggenheim | Sell → Neutral |
2019-12-12 | Downgrade | Raymond James | Outperform → Mkt Perform |
2019-11-12 | Downgrade | JP Morgan | Neutral → Underweight |
2019-11-07 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2019-07-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
2019-07-11 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2019-07-08 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
2019-06-11 | Iniziato | Barclays | Equal Weight |
2019-05-21 | Aggiornamento | Raymond James | Mkt Perform → Strong Buy |
2019-03-20 | Iniziato | SunTrust | Buy |
2019-03-08 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
2018-12-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2018-10-16 | Downgrade | SunTrust | Buy → Hold |
2018-08-13 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2018-07-23 | Iniziato | Morgan Stanley | Overweight |
2018-06-22 | Iniziato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie
What analysts say about Amneal Pharmaceuticals Inc. stockSignificant capital appreciation - Autocar Professional
What drives Amneal Pharmaceuticals Inc. stock priceGame-changing capital returns - Autocar Professional
Amneal Pharmaceuticals Inc. Stock Analysis and ForecastHigh-return market picks - jammulinksnews.com
Is Amneal Pharmaceuticals Inc. a good long term investmentFree Stock Selection - jammulinksnews.com
Amneal Announces Proposed Refinancing of Existing Credit - GlobeNewswire
Amneal reports 3% revenue growth in Q2, advances deleveraging - Investing.com India
Amneal (AMRX) targets $2.55B debt refinancing via loans & notes | AMRX SEC FilingForm 8-K - Stock Titan
Amneal Pharmaceuticals Reports Preliminary Q2 2025 Financial Results Indicating Growth and Deleveraging Efforts - Quiver Quantitative
Amneal Pharmaceuticals Unveils Massive $2.55 Billion Debt Restructuring PlanWhat's Changing - Stock Titan
Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Canada - The Manila Times
Thérapeutique Knight annonce le dépôt d’une nouvelle soumission réglementaire pour CREXONT® (carbidopa et lévodopa) au Canada en capsules à libération prolongée - GlobeNewswire Inc.
Parkinson's Disease Pipeline 2025: MOA and ROA Insights, - openPR.com
Amneal Pharmaceuticals (AMRX) Announces FDA Approval of Prednisolone Acetate Ophthalmic Suspension - MSN
Amneal to Report Second Quarter 2025 Results on August 5, 2025 - GlobeNewswire
Amneal Earnings: How to Join Q2 2025 Results Call on August 5 - Stock Titan
Riot Platforms selling more Bitfarms (BITF) - The Globe and Mail
Analysts Bullish as Amneal Pharmaceuticals, Inc. (AMRX) Director Sells Over 94K Shares - Yahoo Finance
Has Amneal Pharmaceuticals (AMRX) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Kashiv’s Xolair Biosimilar Nears US And EU Filings As Phase III Data Reports - insights.citeline.com
5 Revealing Analyst Questions From Amneal’s Q1 Earnings Call - FinancialContent
Amneal reports positive phase 3 results for XOLAIR biosimilar By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals Breaks Above 200-Day Moving AverageBullish for AMRX - Nasdaq
Investing in Amneal Pharmaceuticals (NASDAQ:AMRX) three years ago would have delivered you a 157% gain - simplywall.st
Insider Sell: Gautam Patel Sells 94,906 Shares of Amneal Pharmac - GuruFocus
Insider Sell: Gautam Patel Sells 94,906 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus
Parkinson’s Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | AbbVie, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevance, Amneal Pharma, Pharma Two B, Jazz Pharma - Barchart.com
Parkinson's Disease Market to Show Remarkable Growth Trends - openPR.com
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? - Yahoo Finance
Epinephrine Autoinjector Market Size, Share, and Competitive - openPR.com
FDA approves Amneal’s prednisolone acetate eye drops, launch set for Q3 - Investing.com India
FDA approves Amneal's prednisolone acetate ophthalmic suspension - Eyes On Eyecare
Insider Sell: Gautam Patel Sells 56,426 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus
Amneal Pharmaceuticals receives U.S. FDA approval for prednisolone acetate - TipRanks
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension - MarketScreener
Amneal Pharmaceuticals (AMRX) Gains FDA Approval for Eye Drug | AMRX Stock News - GuruFocus
FDA Green Lights Amneal's $201M Generic Eye Drug: Q3 2025 Launch Set for Pred Forte Alternative - Stock Titan
Amneal Recalls Oral Antibiotic Over Contamination Issue - Infectious Disease Advisor
Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics space - MSN
Amneal Pharmaceuticals at Goldman Sachs Conference: Strategic Growth Vision By Investing.com - Investing.com Canada
Amneal Pharmaceuticals Inc Azioni (AMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):